Navigation Links
AxoGen, Inc. to Highlight Products at the American Academy of Orthopedic Surgeons 2013 Meeting
Date:3/18/2013

Alachua, FL (PRWEB) March 18, 2013

AxoGen, Inc. (OTCBB: AXGN), a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today that it will be highlighting its products at the American Academy of Orthopedic Surgeons (AAOS) 2013 Annual Meeting, March 19-22, 2013 at McCormick Place in Chicago. The AxoGen booth (#4750) will be featured in the First-Time Exhibitor section where attendees can view new and exciting technologies in orthopedic surgery.

Jill Schiaparelli, Senior Vice President, Business Strategy & Marketing, said, “AxoGen is excited to be presenting at the AAOS 2013 Annual Meeting for the first time. There has been increasing demand for our products by orthopedic surgeons who repair injured peripheral nerves.     The AAOS 2013 meeting is the largest orthopedic meeting in the world and an excellent opportunity to highlight our nerve repair technologies with this important market segment. Our booth will feature our full suite of products: Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector.”

The AAOS has more than 36,000 members worldwide. The Annual Meeting is the largest orthopedic meeting in the world, featuring presentations of scientific papers, scientific poster and technical exhibits, instructional courses, educational symposia, and company exhibits.

About AxoGen, Inc.
AxoGen (AXGN) is a regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company’s innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen’s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ECM coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. For more information, visit our website at http://www.axogeninc.com.

AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL. To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10540559.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. AxoGen, Inc. Appoints Shawn McCarrey as Vice President of Sales
2. AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at American Society for Peripheral Nerve & American Society for Reconstructive Microsurgery 2013 Meetings
3. AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at American Association for Hand Surgery 2013 Annual Meeting
4. AxoGen, Inc. to sponsor Educational Symposium and Panel Discussion at 2013 Annual Meetings of American Association for Hand Surgery, American Society for Peripheral Nerve, and American Society for Reconstructive Microsurgery
5. TGen findings highlighted at 7th annual cancer conference
6. Highlights on women, minorities and persons with disabilities in science and engineering
7. Eldon James Highlights Eco-Friendly Tubing and Fitting Assemblies at MedTec Europe
8. New IOM report highlights PEPFARs successes
9. Enhanced Microsoft SharePoint 2013 and Microsoft Office 365 Support Highlights Release of AvePoint’s DocAve 6 Service Pack 2
10. Research from the 2013 Genitourinary Cancers Symposium highlights new insights on high-risk prostate cancer prevalence and treatment, compares benefit of surveillance and surgery for management of small kidney tumors
11. Mileage Ads Highlights Publishers Can Earn More At MileageAds.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... It is vital for any ... useful, properly analyzed data. The team at Beckman Coulter has designed Kaluza, templates with ... speed' and the need to operate in a GLP (Good Laboratory Practice) fashion. , ...
(Date:12/7/2016)... ... 2016 , ... When it came time to blow out his candles on his 14th birthday, ... Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his family with a ... heart transplant recipient. , “He was playing at home, when we got the phone ...
(Date:12/7/2016)... PITTSBURGH, PA (PRWEB) , ... December 07, 2016 , ... ... and regular changing of the securement tape is painful for her. "This is why ... cannula’s to patients’ heads," she said. , They then created a prototype of the ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... to announce that its fully redesigned website, which launched October 17, 2016, features ... sleek responsive design and easy-to-navigate layout. Visitors and patients can discover the latest ...
(Date:12/7/2016)... Studio City, CA (PRWEB) , ... December 07, 2016 , ... ... number during the holidays and winter seasons. One major study analyzing heart attacks ... January compared to August of a given year. We would all agree of course–no ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)...  Lannett Company, Inc. (NYSE: LCI ) today announced ... Prescription for Success Healthcare Conference on December 14, 2016 at 9:20 ... York City . In addition, the company will ... 4 th Annual Boston Healthcare Conference taking place on December ... ...
(Date:12/6/2016)... CONCORD, Mass. , Dec. 6, 2016  Alopexx ... of DI-Leu16-IL2, a recombinant antibody fusion protein (immunocytokine) composed ... antibody recognizes the same target on B cells as ... and cytokine components but is also involved in tumor ... an anti-cancer vaccine effect. The results of the study ...
(Date:12/6/2016)... , Dec. 6, 2016 Diabetes & Obesity ... diabetes and obesity disease cluster is currently dominated by ... type 2 diabetes mellitus (T2DM), and the majority of ... of products, is attributable to these indications. While products ... market presence, there are a large number of these ...
Breaking Medicine Technology: